HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mary CEO ‘Not Too Concerned’ About China’s CBD Cosmetics Ban

Executive Summary

Mary Agrotechnologies CEO Frank Qin says he is “not too concerned” about China's recent  CBD cosmetics ban, despite his company's plans to build a 150,000 square-foot cultivation and extraction plant in Yunnan, with the aim of supplying the domestic CBD market and exporting overseas.

You may also be interested in...



China’s CBD Cosmetics Shutdown Not Harshing Yooma’s Mellow

Yooma Wellness, a producer of cannabinoid ingredients and owner of brands including What the Hemp, says better-than-expected growth in other markets should offset the impact of China’s ban on CBD in cosmetics.

UK FSA Finalizes Public CBD List Comprising Almost 12,000 Products

The UK Food Standards Agency has published the final update to its public CBD list following what Canna Consultants' Matt Lawson describes as a regulatory “baptism of fire.” There are now 11,908 products permitted to remain on the UK market once those classed as “removed” are taken into account. These products will either progress to the “validated” stage of the UK's novel food process or also be removed.
 

Digital Home-Testing Is The Future, Says Bloom Diagnostics Co-Founder Angelica Kohlmann

With its lateral flow at-home tests for ferritin, thyroid function and ovarian reserves, Swiss medtech firm Bloom Diagnostics thinks it has seen the future of consumer healthcare. HBW Insight speaks to co-founder and board chair Angelica Kohlmann about the firm's Bloom Lab technology and forward-looking plans, including a possible US launch. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel